tldrdailynews.com logo
Tag

Pfizer

All articles tagged with #pfizer

RFK Jr.'s Lyme pledge collides with vaccine history as Pfizer pushes a new jab
health11 days ago

RFK Jr.'s Lyme pledge collides with vaccine history as Pfizer pushes a new jab

RFK Jr., as HHS secretary, pledges stronger action on Lyme disease with better diagnostics and treatment, but his anti-vaccine stance complicates Pfizer/Valneva’s plan to file a Lyme vaccine—the first in more than two decades. The prior Lyme vaccine Lymerix faced safety questions and weak uptake, illustrating the challenges Pfizer now faces, even as Lyme incidence rises with climate-driven tick expansion and researchers pursue vaccines and other preventive tools.

via CNN|
#health#lyme-disease#lymerix
New Four-Dose Lyme Vaccine Shows About 70% Protection
health13 days ago

New Four-Dose Lyme Vaccine Shows About 70% Protection

Pfizer and Valneva announced phase 3 results for PF-0730740, a four-dose Lyme disease vaccine that achieved about 70% efficacy in preventing infection among people aged 5+ across the US, Canada, and Europe. The regimen requires four injections (two two months apart, then months five–nine, then one year later) and the vaccine is not yet approved; its impact on disease complications is unknown, but it could offer meaningful protection for those in endemic areas while continued tick-prevention steps remain important.

via Women's Health|
#health#lyme-disease#pfizer
Lyme Vaccine Delivers Promising 70%+ Protection in Major Trial, Heads to FDA Review
health17 days ago

Lyme Vaccine Delivers Promising 70%+ Protection in Major Trial, Heads to FDA Review

Pfizer and Valneva’s VALOR Phase III trial for PF-07307405 shows about 73% efficacy at preventing confirmed Lyme disease, but the primary endpoint's 95% confidence interval is wide (15.8%–93.5%), likely due to milder Lyme activity during the study; a separate analysis confirms the lower bound above 20%, supporting FDA-approval steps. The vaccine targets the OspA protein to block Borrelia burgdorferi in ticks, and if approved could significantly boost Lyme prevention for high-risk groups.

via Gizmodo|
#clinical-trial#health#lyme-disease
Lyme vaccine shows strong efficacy in late-stage results but misses primary endpoint
health19 days ago

Lyme vaccine shows strong efficacy in late-stage results but misses primary endpoint

Pfizer and Valneva's Lyme disease vaccine posted 73.2% efficacy starting 28 days after the fourth dose in a late-stage trial, but the study missed its primary endpoint under the worst-case scenario (15.8% efficacy in the initial analysis); a second analysis showed 74.8% efficacy, leading to plans for regulatory submissions, with no Lyme vaccine currently approved.

via NBC News|
#clinical-trial#health#lyme-disease
Pfizer pushes ahead with Lyme vaccine despite late-stage trial miss
business19 days ago

Pfizer pushes ahead with Lyme vaccine despite late-stage trial miss

Pfizer intends to seek FDA approval for its Lyme disease vaccine candidate even after a late-stage trial failed to meet statistical goals due to too few Lyme cases; the company says efficacy exceeded 70% in vaccine recipients versus placebo, which they consider strong enough to move forward. Partner Valneva projects up to $1 billion in peak annual sales. The Phase 3 study started with about 18,000 participants but was reduced to roughly 9,400 due to site-quality issues, and Pfizer reports no safety concerns; the vaccine requires three initial doses followed by a booster and targets the outer surface protein A of the bacteria.

via CNBC|
#business#lyme-disease#pfizer
Most TrumpRx-listed drugs have cheaper generics, study finds
healthcare2 months ago

Most TrumpRx-listed drugs have cheaper generics, study finds

TrumpRx’s price list shows many branded meds have cheaper generic alternatives: for example, Pristiq can be found for about $200 for 30 days, while generics cost under $30 and even as low as $16.65 on CostPlusDrugs. Experts warn the site may not benefit cash buyers and could steer patients toward pricier branded options, though the White House says it aims to offer the lowest-cost branded choices. Regulators note generics are generally safe and equivalent, though some critics point to FDA testing gaps highlighted by investigations.

via Axios|
#costplusdrugs#drug-pricing#generics
Pfizer's long-acting obesity shot shows promise with monthly dosing in mid-stage trial
business2 months ago

Pfizer's long-acting obesity shot shows promise with monthly dosing in mid-stage trial

Pfizer reported mid-stage results for PF′3944, an ultra-long-acting GLP-1 obesity drug, showing up to 12.3% weight loss vs placebo at week 28 and about 10.5% when including discontinuations, with no plateau after switching to monthly dosing—suggesting continued weight loss through week 64. The data imply monthly dosing could match weekly regimens, offering convenience in a market led by Eli Lilly and Novo Nordisk. Pfizer plans 10 phase 3 trials this year; modeling suggests a higher monthly dose could achieve roughly 16% weight loss at week 28. The drug was generally well tolerated with mostly mild to moderate GI side effects and some discontinuations due to side effects in both weekly and monthly phases.

via CNBC|
#business#glp-1#monthly-dosing
Pfizer bets on Metsera and cost cuts as Q4 beats amid waning Covid sales
business2 months ago

Pfizer bets on Metsera and cost cuts as Q4 beats amid waning Covid sales

Pfizer beat Q4 estimates with adjusted EPS of 66 cents on $17.56 billion in revenue, despite weaker demand for its Covid vaccine and Paxlovid; it reaffirmed a modest 2026 outlook, plans about $7.7 billion in cost cuts by 2027, and is betting on long-term growth from the Metsera acquisition, including obesity therapy data, while facing ongoing price pressure in Medicaid and competitive pressures on older drugs.

via CNBC|
#business#covid-19#earnings
Pfizer's Q4 Preview: Beat Likely, but Upside Hinges on Drug Updates and US Pricing Policy
business2 months ago

Pfizer's Q4 Preview: Beat Likely, but Upside Hinges on Drug Updates and US Pricing Policy

Pfizer is set to report Q4 earnings before the open, with expectations for EPS of $0.57 on about $16.85 billion in revenue, continuing its streak of beating earnings in 15 of the last 16 quarters. Yet upside looks limited given 2026 guidance, so focus may shift to new drug data (VESPER-3 obesity study, Lyme vaccine, prostate cancer treatment, NSCLC therapy) and potential US pricing pressure from Medicare negotiations starting in 2028. Options imply roughly a 3.6% move post-earnings, and Wall Street holds a Moderate Buy with a around $28.5 average target (AI target about $29).

via TipRanks|
#business#earnings#medicare-price-negotiations
Dividend Stocks Set for a 2026 Comeback as Rates Stay Low
business2 months ago

Dividend Stocks Set for a 2026 Comeback as Rates Stay Low

High-quality dividend stocks are expected to rally as government actions likely keep long-term rates suppressed, making cash less attractive. The piece highlights sustainable payers like SCHD, mispriced midstream names such as ONEOK, and value plays like Pfizer and Conagra Brands, noting OKE's 5.6% yield and potential upside if multiples normalize, while warning inflation and sector headwinds require selective stock picking.

via Seeking Alpha|
#business#conagra-brands#dividend-stocks